Compare Immunome, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 2,744 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.03
-74.03%
10.40
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
198.42%
0%
198.42%
6 Months
90.0%
0%
90.0%
1 Year
64.55%
0%
64.55%
2 Years
456.0%
0%
456.0%
3 Years
683.68%
0%
683.68%
4 Years
50.31%
0%
50.31%
5 Years
0%
0%
0.0%
Immunome, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
92.00%
EBIT Growth (5y)
-275.68%
EBIT to Interest (avg)
-150.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.27
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.59
EV to EBIT
-2.59
EV to EBITDA
-2.63
EV to Capital Employed
-46.79
EV to Sales
43.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-55.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 42 Schemes (46.96%)
Foreign Institutions
Held by 78 Foreign Institutions (13.62%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
4.00
2.90
37.93%
Operating Profit (PBDIT) excl Other Income
-45.80
-43.90
-4.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.40
-41.60
-4.33%
Operating Profit Margin (Excl OI)
-11,576.10%
-15,255.00%
367.89%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 37.93% vs 7.41% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -4.33% vs 48.13% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9.00
14.00
-35.71%
Operating Profit (PBDIT) excl Other Income
-151.40
-108.80
-39.15%
Interest
0.00
0.00
Exceptional Items
-152.30
0.00
Consolidate Net Profit
-293.00
-106.80
-174.34%
Operating Profit Margin (Excl OI)
-16,973.30%
-7,813.50%
-915.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -35.71% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -174.34% vs -189.43% in Dec 2023
About Immunome, Inc. 
Immunome, Inc.
Pharmaceuticals & Biotechnology
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
Company Coordinates 
Company Details
665 STOCKTON DRIVE, SUITE 300 , EXTON PA : 19341
Registrar Details






